Ophthalmic compositions comprising lifitegrast particles and semifluorinated alkanes
The ophthalmic composition with lifitegrast particles in a semifluorinated alkane provides stable and effective treatment of ocular disorders by ensuring rapid and consistent delivery, addressing the need for preservative-free and antioxidant-free formulations.
Patent Information
- Application Number
- PCT/EP2026/062992
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-27
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for improved ophthalmic compositions that are stable, sterile, and free or substantially free of potentially irritating antioxidants and preservatives, while providing effective treatment of ocular disorders such as dry eye disease with rapid and consistent delivery of lifitegrast.
An ophthalmic composition comprising lifitegrast particles with a D90 particle diameter of about 10 μm or less and a D50 particle diameter of about 7 μm or less, suspended in a semifluorinated alkane such as perfluorohexyloctane, which acts as a stable, non-aqueous vehicle for lifitegrast, eliminating the need for additional ingredients and ensuring patient comfort.
The composition achieves stable and effective delivery of lifitegrast to the eye, reducing the sensation of grittiness and enhancing treatment efficacy without the use of preservatives, allowing for a multi-dose format and minimizing ocular damage.
Smart Images

Figure EP2026062992_12112026_PF_FP_ABST
Abstract
Description
OPHTHALMIC COMPOSITIONS COMPRISING LIFITEGRAST PARTICLES AND SEMIFLUORINATED ALKANES
[0001] This application claims the benefit of United States Patent Application 63 / 800,725, filed May 6th 2025, and European Patent Application 25178991.3, filed 27th May 2025, the complete contents of which are incorporated herein by reference.
[0002] The invention relates to an ophthalmic composition in the form of a suspension comprising (a) I ifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less.BACKGROUND
[0003] Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a multifunctional disorder of the tear film and ocular surface which results in discomfort, visual disturbance, and often even in ocular surface damage. Secondary diseases whose development may be triggered by DED include filamentary keratitis, microbial keratitis, corneal neovascularisation, and ocular surface keratinisation. Two major categories of dry eye disease are distinguished today, which are aqueous-deficient DED and evaporative DED. These conditions are not necessarily mutually exclusive.
[0004] Within the class of aqueous-deficient forms of dry-eye disease, two major subtypes are differentiated, Sjogren and non-Sjdgren. Evaporative DED is associated with increased evaporative loss of the tear film and can develop as a result of diverse root causes including meibomian gland disease, eyelid aperture disorders, blink disorders (as in Parkinson disease) or ocular surface disorders (as in allergic conjunctivitis).
[0005] Typically, ophthalmic compositions for treatment of dry eye disease are administered as eye drops, with one or more drops of the composition being applied to an eye of the subject suffering from or susceptible to the disease one or more times per day, although the frequency of administration of such compositions may be dependent on multiple factors, including the makeup of the particular composition.
[0006] Lifitegrast (the active ingredient of Xiidra®) is a small molecule lymphocyte function-associated antigen 1 (LFA-1) antagonist that has been approved for the treatment of signs and symptoms of dry eye disease. It has the following structure:
[0007] Despite the success of Xiidra in meeting the needs of many patients suffering from dry eye disease, there remains a need for improved dry eye disease treatments, particularly those that are stable, sterile, and having lesser concentrations of or even substantially free of potentially irritating antioxidants and / or preservatives.
[0008] Disclosed herein and in PCT / EP2024 / 082568 are improved, stable ophthalmic compositions comprising (a) lifitegrast; and (b) at least one semifluorinated alkane. These compositions may be preservative-free and / or free of antioxidants. Without wishing to be bound by theory, it is believed that, not only does the at least one semifluorinated alkane provide its own ocular disorder treatment and / or prevention effect (thus intersecting the disease cycle with effects on both inflammation and tear evaporation), but it also acts as a stable, non-aqueous vehicle or carrier for the lifitegrast. The non-aqueous nature also allows for the reduction or elimination of the need for additional ingredients, such as antioxidants and / or preservatives. This circumvents the potential for ocular damage from preservatives, which is particularly high among patients suffering from chronic diseases, such as dry eye disease, that require daily eye drop instillations for periods of years to decades. Moreover, the ability to prepare a product which does not need an extrinsic preservative means that it can be provided in a multi-dose format, which reduces the waste and cost associated with packaging materials. The unique combination of the lifitegrast and the at least one semifluorinated alkane thus provides improved, stable ophthalmic compositions. Furthermore, the compositions can achieve similar ocular exposure as aqueous lifitegrast compositions but with only one third of the dose.
[0009] There is a need for improved ophthalmic compositions comprising (a) lifitegrast and (b) at least one semifluorinated alkane which promote rapid and consistent delivery of lifitegrast to the eye and provide effective treatment of ocular disorders, whilst ensuring patient comfort.SUMMARY OF THE INVENTION
[0010] The inventors have found that certain particle diameters for the lifitegrast or a pharmaceutically acceptable salt thereof avoid the sensation of grittiness in the eyeand improve the speed and consistency of lifitegrast delivery to the eye. Specifically, the invention relates to an ophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less. Preferably, the ophthalmic composition of the invention consists of (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) perfluorohexyloctane (F6H8). It has been surprisingly found that a composition consisting only of these two ingredients is stable and provides improved delivery of lifitegrast relative to an aqueous solution of lifitegrast. Moreover, limiting the composition to these two ingredients simplifies manufacture of the composition, whilst the composition is effective for treating ocular disorders such as dry eye disease without the addition of any further compounds to the eye.
[0011] This and other features, aspects, and advantages of the disclosure will be apparent from a reading of the following.Definitions
[0012] Definitions of certain terms as used in this application are provided below. Unless defined otherwise, all technical and scientific terms used herein have the normal and common meaning that would be commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0013] As used herein, the term “about” means approximately, in the region of, roughly, or around. The term “about” in relation to a numerical value x is optional and means, for example, x ± 5%. Numerical values disclosed with the term “about” include the specifically identified value. For example, “about 100” means a number ranging from 95 to 105, including 95, 100, and 105.
[0014] As used herein, “administration” of a compound or composition to a patient refers to any route of introducing or delivering the compound or composition to a subject. Administration includes self-administration and the administration by another.
[0015] As used herein, a “condition,” “disorder,” or “disease” refers to any unhealthy or abnormal state.
[0016] As used herein, an “effective amount” or “effective dose” refers to an amount of a compound or composition that treats and / or temporarily prevents, upon single or multiple dose administration, a patient suffering from a disorder, disease, or condition. An effective amount can be determined by the attending diagnostician through the use of known techniques and by observing results obtained under analogouscircumstances. In determining the effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of patient; its size, age, and general health; the specific condition, disorder, or disease involved; the degree of or involvement or the seventy of the condition, disorder, or disease, the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
[0017] As used herein, a composition is “free” of a component when it comprises no detectable amount of the component.
[0018] As used herein, the term “consists essentially of” means that, in addition to the mandatory ingredients, specific further ingredients can be present, namely those not materially affecting the essential characteristics of the composition or component in question. Compositions or components herein which “consist essentially of’ the specified ingredients may consist only of the specified ingredients, with no other ingredients present (in which case the composition “consists of” the specified ingredients).
[0019] As used herein, the terms “patient,” “subject,” “individual,” and the like, as used herein, are interchangeable and refer to any animal, which may be a human or a nonhuman animal. Compositions of the invention are particularly suited to use in humans and so the patient is preferably a human.
[0020] As used herein, the terms “prevention” of or “preventing” a disorder, disease, or condition refers to reducing the severity and / or the occurrence of the disorder, disease, or condition in a treated sample relative to an untreated control sample, and includes delaying onset and / or progression of the disorder or condition relative to the untreated control sample.
[0021] As used herein, the term “ocular disorder” refers to any of the signs, symptoms, and / or underlying cause(s) of any physiological disorder that affects the eye or vision.
[0022] As used herein, the term “particle diameter” refers to the equivalent spherical diameter (esd), i.e., the diameter of a sphere having the same volume as a given particle. The terms “Dn” and “Dnparticle diameter” refer to the diameter below which n% by volume of the particle population is found. Thus, the terms “Dso” and “Dso particle diameter” refer to the volume-based median particle diameter below which 50% by volume of the particle population is found, and the terms “D90” and “D90 particle diameter” refer to the particle diameter below which 90% by volume of the particlepopulation is found. Particle diameters can be determined by laser diffraction, for example in accordance with U.S. Pharmacopeia chapter <429>, 2024. The particle diameter of I ifitegrast or a pharmaceutically acceptable salt thereof, such as the D90 or D50 particle diameter, in at least one semifluorinated alkane may be determined using routine laser diffraction methods. In particular, the particle diameter may be determined using a light diffraction particle analyser (e.g., Horiba LA-960) preferably equipped with a circulation system (e.g., Horiba MiniFlow), for example using the LA-960 for Windows V8.40 software. The particle size may be determined using Mie theory, for example using a real and imaginary refractive index of 1.643 and 0.1 respectively. Preferably, a dispersant, such as 0.1% (w / w) sorbitan monooleate (e.g. Span® 80) in heptane, may be added to improve the separation of the lifitegrast particles. Optionally, the mixture of lifitegrast suspension and dispersant consists of about 1% (w / w) suspension and about 99% (w / w) dispersant.
[0023] As used herein, a “pharmaceutically acceptable excipient” refers to a carrier or an excipient that is useful in preparing a pharmaceutical composition. For example, a pharmaceutically acceptable excipient is generally safe and includes carriers and excipients that are generally considered acceptable for mammalian pharmaceutical use. As a non-limiting example, pharmaceutically acceptable excipients may be solid, semi-solid, or liquid materials which, in the aggregate, can serve as a vehicle or medium for active ingredients. Some examples of pharmaceutically acceptable excipients are found in Remington’s Pharmaceutical Sciences and Rowe’s Handbook of Pharmaceutical Excipients and include diluents, vehicles, carriers, ointment bases, binders, stabilizing agents, preservatives, solvents, suspending agents, and others. In the ophthalmic compositions of the present disclosure, the at least one semifluorinated alkane is not a “pharmaceutically acceptable excipient” because it provides its own ocular disorder treatment and / or prevention effect.
[0024] As used herein, a container closure system is the sum of packaging components that collectively contain the ophthalmic composition. For example, the container closure system may consist of a bottle, a droplet-forming outlet, and a screw cap. Alternatively, the container closure system may consist of a vial, which is integrally formed with a droplet forming outlet, and a cap that forms an interference fit with the droplet forming outlet.
[0025] As used herein, a “bottle” is a container for storing and dispensing a liquid ophthalmic composition, having a neck, a body that is wider than the neck, and a base that allows the bottle to stand upright on a flat surface. The body of the bottle is squeezable by hand to dispense the composition through the neck.
[0026] As used herein, a “vial” is a container for storing and dispensing a liquid ophthalmic composition. It is squeezable by hand to dispense the composition through an outlet. The vial typically is or forms part of a multi-dose container closure system. The vial may comprise a body that is integrally formed with a droplet-forming outlet. The vial may comprise a neck at one end, with a circular cross section, and may be crimped at the other end to form a seal, giving an elliptical cross-section through the body of the vial. Unlike a bottle, a vial lacks a base that allows it to stand upright on a flat surface.
[0027] As used herein, a “pharmaceutically acceptable salt” is a salt that is suitable for use in contact with tissues of humans without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, N+H3(Ci-4alkyl) and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Examples of pharmaceutically acceptable acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
[0028] As used herein, a composition is “stable” if the lifitegrast within the composition degrades by less than about 10% (i.e., at least 90% of the lifitegrast is intact) after being stored at about 25 °C for 10 weeks, as measured by high-performance liquidchromatography (HPLC) or an equivalent appropriate technique such as that within the U.S. Pharmacopeia, preferably by HPLC.
[0029] As used herein, a composition is “sterile” if it has a microbial bioburden of less than or equal to 0.1 CFU / ml, as measured by a standard plate count method or an equivalent appropriate technique such as that within the U.S. Pharmacopeia.
[0030] As used herein, a substance, composition, or container closure system is “sterilised” if the substance, composition, or container closure system has been subjected to a sterilisation process, such as sterilisation by ethylene oxide or gamma irradiation.
[0031] As used herein, the term “treat,” “treating,” or “treatment,” when used in connection with a disorder or condition, includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the disorder or condition. Improvements in or lessening the seventy of any symptom of the disorder or condition can be readily assessed according to standard methods and techniques known in the art.
[0032] As will be understood by one of ordinary skill in the art, each range disclosed herein includes all possible subranges as well as individual numerical values within that range, including endpoints. As a non-limiting example, a range of “0.001% to 0.02%” includes the endpoints of 0.001% and 0.02% and would be understood to specifically disclose subranges such as “0.004% to 0.01%,” “0.005% to 0.02%,” etc., as well as all individual numbers within the disclosed range, for example, 0.001%, 0.004%, 0.005%, 0.01%, 0.02%, etc.
[0033] Any percentage concentration values disclosed herein are on a weight-per-weight (w / w) basis unless otherwise specified.
[0034] Unless specifically stated, a process or method comprising a step of mixing two or more components does not require any specific order of mixing. Thus, components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
[0035] The various steps of the methods or processes herein may be carried out at the same time or at different times, in the same or different geographical locations, e.g., countries, and by the same or different people or entities.DETAILED DESCRIPTIONOphthalmic composition
[0036] The ophthalmic composition of the present invention is in the form of a suspension and comprises (a) I ifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less. The lifitegrast is present as particles suspended in the semifluorinated alkane liquid, since lifitegrast is insoluble in semifluorinated alkanes.
[0037] The ophthalmic composition of the present invention may be in the form of a suspension and consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less.
[0038] The combined weight of the (a) lifitegrast or a pharmaceutically acceptable salt thereof and the (b) at least one semifluorinated alkane may be more than 99.5% (w / w) of the total weight of the ophthalmic composition.
[0039] Preferably, the ophthalmic composition of the present invention is in the form of a suspension and consists of (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less. The ophthalmic composition may consist of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) no more than two semifluorinated alkanes. More preferably, the ophthalmic composition consists of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane (F6H8). Further preferably, the ophthalmic composition consists of: (a) about 2% (w / w) to about 8% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, such as about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) perfluorohexyloctane (F6H8). Even more preferably, the ophthalmic composition consists of: (a) about 2% (w / w) to about 6% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, for example about 2.5% (w / w) to about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) perfluorohexyloctane (F6H8).
[0040] Preferably, the ophthalmic composition is a stable liquid composition. The ophthalmic composition may be a stable non-aqueous liquid composition.
[0041] The ophthalmic composition is preferably a sterile liquid composition. More preferably, the ophthalmic composition is a sterile non-aqueous liquid composition. (a) Lifitegrast
[0042] The ophthalmic composition comprises (a) lifitegrast or a pharmaceutically acceptable salt thereof. The lifitegrast in the composition may be present in the form of a pharmaceutically acceptable salt, but is most preferably present in the form of lifitegrast free acid. When lifitegrast is present in the form of a pharmaceutically acceptable salt, the pharmaceutically acceptable salt is preferably selected from sodium, potassium, arginine, and tris(hydroxymethyl)aminomethane salts, more preferably a sodium salt. Where a salt is used, concentrations or amounts of lifitegrast disclosed herein are calculated according to the corresponding quantity of lifitegrast free acid, i.e. on a free acid basis.
[0043] Lifitegrast or a pharmaceutically acceptable salt thereof may be included in the composition at a concentration from about 0.1% (w / w) to about 10% (w / w), for example, from about 1% (w / w) to about 10% (w / w), from about 2% (w / w) to about 10% (w / w), from about 2% (w / w) to about 8% (w / w), from about 2% (w / w) to about 6% (w / w), or from about 2.5% (w / w) to about 5% (w / w) on a free acid basis. A composition having a concentration of at least 2% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis is preferred because it is stable (i.e., little or no sedimentation is observed during prolonged storage) at suitable particle diameters, as shown in the examples. Most preferably, the concentration of lifitegrast or a pharmaceutically acceptable salt thereof is about 2.5% (w / w) or about 5% (w / w) on a free acid basis.
[0044] The inventors have found that a D90 particle diameter of about 10 pm or less improves patient comfort by preventing a sensation of grittiness in the eye. Thus, in the ophthalmic composition of the present disclosure, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter of about 10 pm or less, for example from about 3 pm to about 10 pm. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter of about 7 pm or less, for example from about 3 pm to about 7 pm. At a D90 particle diameter of about 7 pm or less, the delivery of lifitegrast to the target site is not limited by its dissolution rate, leading to improved drug delivery.
[0045] The inventors have further found that a D50 particle diameter of about 7 pm or less provides a suspension that has acceptable sedimentation behaviour across a wide range of lifitegrast concentrations and ideal or close to ideal sedimentation behaviour (i.e., a sedimentation volume of 1 or close to 1) at lifitegrast concentrationsof 2% or greater (w / w) of the composition, which is preferred for the efficacy of the ophthalmic composition. Thus, in the ophthalmic composition of the present disclosure, the I ifitegrast or a pharmaceutically acceptable salt thereof may have a Dso particle diameter of about 7 pm or less, for example from about 0.2 pm to about 7 pm, for example from about 0.5 pm to about 7 pm. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter of about 4 pm or less, for example from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm. A particle diameter of about 4 pm or less improves the stability of the suspension since less settling is observed during storage, as shown in the examples. The lifitegrast or a pharmaceutically acceptable salt thereof may have a Dso particle diameter of from about 0.2 pm to about 1 pm, for example a Dso particle diameter of about 0.4 pm. Without being bound by theory, it is believed that smaller particle size may further enhance penetration through the ocular surface which may in turn enhance efficacy. It will naturally be understood that a reduction in Dso particle diameter will typically be accompanied by an associated reduction in D90 particle diameter.
[0046] The lifitegrast or a pharmaceutically acceptable salt thereof may have (i) a D90 particle diameter of about 10 pm or less, for example from about 3 pm to about 10 pm, and (ii) a Dso particle diameter of about 7 pm or less, for example from about 0.2 pm to about 7 pm, for example from about 0.5 pm to about 7 pm. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of about 10 pm or less, for example from about 3 pm to about 10 pm, and (ii) a Dso particle diameter of about 4 pm or less, for example from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm. More preferably, the lifitegrast or a pharmaceutically acceptable salt thereof may have (i) a D90 particle diameter of about 7 pm or less, for example from about 3 pm to about 7 pm, and (ii) a Dso particle diameter of about 4 pm or less, for example from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm.
[0047] As shown in the examples, the suspension demonstrates good stability (i.e., there is little or no sedimentation during prolonged storage) when the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter of about 7 pm or less and is present in the ophthalmic composition at a concentration of about 2% (w / w) or more on a free acid basis. Thus, the lifitegrast or a pharmaceutically acceptable salt thereof may have a Dso particle diameter of from about 0.2 pm to about 7 pm, for example from about 0.5 pm to about 7 pm, and be present in the ophthalmic composition at a concentration of from about 2% (w / w) to about 10% (w / w), preferably from about 2% (w / w) to about 8% (w / w) on a free acid basis. The lifitegrast or apharmaceutically acceptable salt thereof may have (i) a D90 particle diameter of from about 3 pm to about 10 pm and (ii) a D50 particle diameter of from about 0.2 pm to about 7 pm, for example from about 0.5 pm to about 7 pm, and be present in the ophthalmic composition at a concentration of from about 2% (w / w) to about 8% (w / w) on a free acid basis.
[0048] The examples demonstrate that ideal or close to ideal sedimentation behaviour is observed when the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter of about 4 pm or less and is present in the ophthalmic composition at a concentration of about 2% (w / w) or more on a free acid basis. Thus, preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter of from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm, and is present in the ophthalmic composition at a concentration of from about 2% (w / w) to about 10% (w / w), preferably from about 2% (w / w) to about 8% (w / w) on a free acid basis. More preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of from about 3 pm to about 10 pm, for example from about 3 pm to about 7 pm, and (ii) a D50 particle diameter of from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm, and is present in the ophthalmic composition at a concentration of from about 2% (w / w) to about 8% (w / w) on a free acid basis.
[0049] The lifitegrast or a pharmaceutically acceptable salt thereof may have a D10 particle diameter of about 2 pm or less, for example from about 0.25 pm to about 2 pm. The lifitegrast or a pharmaceutically acceptable salt thereof may have a D10 particle diameter of about 1.5 pm or less, for example from about 0.5 pm to about 1.5 pm. It will be understood that that particles of lifitegrast or a pharmaceutically acceptable salt thereof may have such a D10 particle diameter whilst having any of the D50 and D90 particle diameters disclosed above.(b) Semifluorinated alkanes
[0050] The ophthalmic composition comprises (b) at least one semifluorinated alkane. Semifluorinated alkanes are linear or branched alkanes with fluorine atoms in place of some of the hydrogen atoms of the corresponding non-fluorinated alkane. In particular, semifluorinated alkanes are compounds composed of at least one perfluorinated hydrocarbon segment and at least one non-fluorinated hydrocarbon segment. According to a nomenclature used herein, the semifluorinated alkanes may be referred to as FnHm, wherein F refers to the perfluorinated hydrocarbon segment (F-segment), H refers to the non-fluorinated hydrocarbon segment (H-segment), and n and m referto the number of carbon atoms of those segments, respectively. For example, F6H8 is used to refer to perfluorohexyloctane.
[0051] This type of nomenclature is typically used for compounds wherein the perfluorinated carbons are bonded together to form a single linear F-segment and the non-fluorinated carbons are bonded together to form a single linear H-segment. Typically, the perfluorinated F-segment is attached to an end of the non-fluorinated H-segment, i.e., it is attached to C1, so that the overall molecule is linear. However, a minority of branched compounds, wherein two linear (F and H) segments are joined at a different position such as C2, may be present. In the case of perfluorohexyloctane (F6H8), the perfluorohexyloctane comprises 95% (w / w) or more of 1 -perfluorohexyloctane, preferably 98% (w / w) or more, more preferably 99.5% (w / w) or more. Preferably, the balance is 2-perfluorohexyloctane.
[0052] The at least one semifluorinated alkane may be included in the composition at a concentration of at least about 90% (w / w), for example, at least about 95% (w / w). The at least one semifluorinated alkane may be included in the composition at a concentration from about 90% (w / w) to about 99.5% (w / w), for example, from about 94% (w / w) to about 98% (w / w).
[0053] The at least one semifluorinated alkane may be chosen from F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may be chosen from F4H4, F4H5, F4H6, F5H5, F5H6, F5H7, F5H8, F6H6, F6H7, F6H8, F6H9, F6H10, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may be chosen from F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, or any combination thereof. Preferably, the composition includes no more than two semifluorinated alkanes.
[0054] Preferably, the at least one semifluorinated alkane comprises at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10). The at least one semifluorinated alkane may consist essentially of at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10).
[0055] More preferably, the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8). Even more preferably, the composition is substantially free of other semifluorinated alkanes besides F6H8. As used herein, a composition may be “substantially free of other semifluorinated alkanes” when the other semifluorinated alkanes are present at a relative amount of 2% (w / w) or less, preferably 1% (w / w) or less, or more preferably 0.5% (w / w) or less based on the totalamount of semifluorinated alkanes in the composition. Most preferably, the only semifluorinated alkane in the composition is F6H8.(c) Other components
[0056] Preferably, the ophthalmic composition is substantially free of pharmaceutically acceptable excipients. As used herein, a composition may be “substantially free of pharmaceutically acceptable excipients” when excipients are present at an amount of 0.5% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of pharmaceutically acceptable excipients.
[0057] The ophthalmic composition may be substantially free of medium chain triglycerides. Medium-chain triglycerides are triglycerides of fatty acids. The fatty acids have an aliphatic chain of 6-12 carbon atoms, and can be, for example, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid. Therefore, a medium chain triglyceride may be a triglyceride of fatty acids, wherein the fatty acids comprise hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid or combinations of two or more thereof. As used herein, a composition may be “substantially free of medium chain triglycerides” when medium chain triglycerides are present at an amount of 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of medium chain triglycerides.
[0058] Medium-chain triglycerides include coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin. Accordingly, the ophthalmic composition may be substantially free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin. As used herein, a composition may be “substantially free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin” when the combined amount of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin present in the composition is 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin.
[0059] The ophthalmic composition may be substantially free of semifluorinated alkyl alcohols. As used herein, a composition may be “substantially free of semifluorinated alkyl alcohols” when semifluorinated alkyl alcohols are present at an amount of0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of semifluorinated alkyl alcohols.
[0060] Preferably, the ophthalmic composition is substantially free of medium chain triglycerides and substantially free of semifluorinated alkyl alcohols. More preferably, the ophthalmic composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.
[0061] The formulation of lifitegrast may comprise one or more antioxidants to prevent oxidative degradation of the lifitegrast. The one or more antioxidants may comprise a thiosulfate salt, such as sodium thiosulfate. The antioxidants may comprise a metabisulfite salt. The antioxidants may comprise sodium bisulfate.
[0062] Other antioxidants which can be used to form pharmaceutical formulations include, but are not limited to, propyl, octyl and dodecyl esters of gallic acid, butylated hydroxyanisole (BHA, usually purchased as a mixture of ortho and meta isomers), green tea extract, uric acid, cysteine, pyruvate, nordihydroguaiaretic acid, ascorbic acid, salts of ascorbic acid such as ascorbyl palmitate and sodium ascorbate, ascorbyl glucosamine, vitamin E (i.e., tocopherols such as a-tocopherol), derivatives of vitamin E (e.g., tocopheryl acetate), retinoids such as retinoic acid, retinol, trans-retinol, cisretinol, mixtures of trans-retinol and cis-retinol, 3-dehydroretinol and derivatives of vitamin A (e.g., retinyl acetate, retinal and retinyl palmitate, also known as tetinyl palmitate), sodium citrate, sodium sulfite, lycopene, anthocyanids, bioflavinoids (e.g., hesperitin, naringen, rutin and quercetin), superoxide dismutase, glutathione peroxidase, butylated hydroxytoluene (BHT), indole-3-carbinol, pycnogenol, melatonin, sulforaphane, pregnenolone, lipoic acid and 4-hydroxy-5-methyl-3[2H]-furanone. In the ophthalmic composition, one or more, or all, of the above antioxidants may be excluded, or may be present in less than effective amounts, either alone or in combination.
[0063] The amount of antioxidants present may be in the range of about 0.01 -about 0.5% w / v. The amount of antioxidants present may be in the range of about 0.1 -about 0.5%, about 0.2-about 0.5%, about 0.3-about 0.5%, about 0.4-about 0.5%, about 0.01 -about 0.4%, about 0.1 -about 0.4%, about 0.2-about 0.4%, about 0.3-about 0.4%, about 0.01 -about 0.3%, about 0.1 -about 0.3%, about 0.2-about 0.3%, about 0.01-about 0.2%, about 0.1-about 0.2%, or about 0.01 -about 0.1% w / v. Sodium thiosulfate may be present in an amount to provide antioxidant stability to the formulation, and the amount of sodium thiosulfate as a percentage by weight of all total antioxidants may be greater than 50% by weight.
[0064] Vitamin E and / or derivatives of vitamin E may be present in an amount to provide antioxidant stability to the formulation, and the amount of vitamin E and / or derivatives of vitamin E as a percentage by weight of all total antioxidants may be greater than 50% by weight.
[0065] The ophthalmic composition may further comprise a preservative. The preservative may be selected from benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro complex, polyquaternium-1 , chlorobutanol, edetate disodium, polyhexamethylene biguanide, a composition containing boric acid, sorbitol, propylene glycol, and zinc chloride (e.g., SofZia™), or combinations thereof.
[0066] The amount of preservatives present may be in the range of about 0.01-0.5% w / v. The amount of preservatives present may be in the range of about 0.1 -about 0.5%, about 0.2-about 0.5%, about 0.3-about 0.5%, about 0.4-about 0.5%, about 0.01 -about 0.4%, about 0.1 -about 0.4%, about 0.2-about 0.4%, about 0.3-about 0.4%, about 0.01 -about 0.3%, about 0.1 -about 0.3%, about 0.2-about 0.3%, about 0.01-about 0.2%, about 0.1 -about 0.2%, or about 0.01 -about 0.1% w / v.
[0067] It is also possible, and preferred, for the ophthalmic composition to be free of antioxidants, thus simplifying its preparation and avoiding potential irritation caused by antioxidant chemicals. The ability to maintain lifitegrast in stable form in compositions of the invention despite the absence of antioxidant is particularly surprising because oxygen is highly soluble in semifluorinated alkanes (and in particular in F6H8). The Xiidra product includes sodium thiosulfate as an antioxidant.
[0068] It is also possible, and preferred, for the ophthalmic composition to be free of preservatives even when it is provided in a multi-dose container, thus simplifying its preparation and avoiding potential irritation caused by known preservatives. Without wishing to be bound by theory, it is believed that the semifluorinated alkane can provide a preservative effect in the composition, as well as providing a therapeutic ocular effect.
[0069] Thus, preferably, the ophthalmic composition is substantially free of antioxidants and / or substantially free of preservatives (save for semifluorinated alkanes, considering these as preservatives). Preferably, the ophthalmic composition is substantially free of the antioxidants listed above and / or substantially free of the preservatives listed above. Further preferably, the ophthalmic composition is substantially free of both antioxidants and preservatives. As used herein, a composition may be “substantially free of antioxidants” when antioxidants are present at an amount of 0.1 % (w / w) or less, preferably 0.05% (w / w) or less, or more preferably 0.01% (w / w) or less. As used herein, a composition may be “substantially free ofpreservatives” when preservatives (save for semifluorinated alkanes, considering these as preservatives) are present at an amount of 0.1% (w / w) or less, preferably 0.05% (w / w) or less, or more preferably 0.01 % (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of the antioxidants listed above and / or free of the preservatives listed above. Further preferably, the ophthalmic composition is free of both antioxidants and preservatives.
[0070] Preferably, the ophthalmic composition is substantially free of water. As used herein, a composition may be “substantially free of water” when the composition comprises water at an amount of 1% (w / w) or less, preferably 0.5% (w / w) or less, or more preferably 0.1 % (w / w) or less, based on the total weight of the composition. The ophthalmic compositions may be free of water.
[0071] Preferably, the ophthalmic composition is substantially free of water and does not contain any pharmaceutically acceptable excipients.Ball milling
[0072] Further disclosed herein is a process for reducing the particle diameter of solid lifitegrast or a pharmaceutically acceptable salt thereof, the process comprising ball milling a suspension of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane. Advantageously, the particle size of the lifitegrast or a pharmaceutically acceptable salt thereof can be reduced whilst it is suspended in the at least one semifluorinated alkane (i.e., there is no need for an alternative or additional liquid medium to effectively mill the lifitegrast particles), which simplifies the overall manufacturing process.
[0073] Also disclosed herein is a process for preparing the ophthalmic composition described above, the process comprising ball milling a suspension of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof. As explained above, the lifitegrast or a pharmaceutically acceptable salt thereof can advantageously be ball milled whilst suspended in the at least one semifluorinated alkane, which simplifies the preparation of the ophthalmic composition.
[0074] The process may comprise micronising the lifitegrast or a pharmaceutically acceptable salt thereof to reduce its particle diameter before it is mixed with the at least one semifluorinated alkane. The use of lifitegrast or a pharmaceutically acceptable salt thereof with a smaller particle diameter, for example a D90 particle diameter of about 10 pm or less, improves the efficiency of the ball milling step,although lifitegrast or a pharmaceutically acceptable salt thereof with a larger D90 particle diameter can be used, as discussed below.
[0075] Ball milling is a technique which can be used to reduce the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof to obtain at least one of (i) a D90 particle diameter of about 10 pm or less, preferably about 7 pm or less, and (ii) a D50 particle diameter of about 7 pm or less, preferably about 4 pm or less, each particle diameter having advantages as described above. It will be understood that the D90 and D50 particle diameters before ball milling will be greater than the particle diameters after ball milling.
[0076] The ball milling may reduce the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof, such as the D90 particle diameter and / or the D50 particle diameter, by at least about 10%, for example from about 10% to about 95% and preferably from about 25% to about 90%. The ball milling may reduce both the D90 particle diameter and the D50 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least about 10%, for example from about 10% to about 95% and preferably from about 25% to about 90%.
[0077] When the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 10 pm or less, the D90 particle diameter before ball milling is typically at least about 11 pm, for example from about 11 pm to about 25 pm. When the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 7 pm or less, the D90 particle diameter before ball milling is typically at least about 8 pm, for example from about 8 pm to about 25 pm or from about 8 pm to about 12 pm.
[0078] When the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 7 pm or less, the D50 particle diameter before ball milling is typically at least about 8 pm, for example from about 8 pm to about 12 pm. When the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 4 pm or less, the D50 particle diameter before ball milling is typically at least about 5 pm, for example from about 5 pm to about 12 pm or from about 5 pm to about 10 pm.
[0079] Thus, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter before ball milling of from about 11 pm to about 25 pm, and a D50 particle diameter before ball milling of from about 8 pm to about 12 pm. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter before ball milling of from about 8 pm to about 12 pm, and a D50 particle diameter before ball milling of from about 5 pm to about 10 pm.
[0080] It will be understood that if targeting a smaller particle diameter then the particle diameter before ball milling may be smaller. So if the target D90 particle diameter is about 6 pm to about 10 pm, the D90 particle diameter before ball milling may be at least about 11 pm. Whereas, if the target D90 particle diameter is about 3 pm to about 5 pm, the D90 particle diameter before ball milling may be smaller, for example about 6 pm to about 10 pm. Similarly, for a target D50 particle diameter of from about 0.5 pm to about 2 pm, the D50 particle diameter before ball milling may be smaller than the about 5 pm to about 10 pm mentioned above, and may instead be about 3 pm to about 5 pm.
[0081] It has been found that certain concentrations of I ifitegrast in the suspension are particularly suitable for ball milling. At lifitegrast concentrations of around 20% (w / w) or above, the suspension forms a paste and the viscosity is too high for the particles to be milled efficiently. At lower concentrations of around 15% (w / w) or below, especially around 10% (w / w), the viscosity is acceptable for ball milling. Moreover, after milling, it is impractical to increase the concentration of lifitegrast particles because semifluorinated alkanes are not volatile and it is therefore difficult to remove semifluorinated alkane after it has been mixed with the lifitegrast particles. A concentration of at least 2% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis is preferred for the efficacy of the ophthalmic composition and therefore the suspension that is subjected to ball milling preferably has a concentration of at least 2% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis. Suspensions having a lifitegrast concentration of above 2% (w / w) have the additional advantage of being stable (i.e. , little or no sedimentation is observed during prolonged storage) at suitable particle diameters. Not only is this advantageous for the final ophthalmic composition (as it promotes consistent delivery of lifitegrast as set out above), but the lack of sedimentation also helps reduce the particle size more efficiently during ball milling. Moreover, the suspension does not need to be redispersed before it is filled into a container closure system.
[0082] The suspension of the lifitegrast or a pharmaceutically acceptable salt thereof and the at least one semifluorinated alkane that is subjected to ball milling may comprise from about 1% (w / w) to about 25% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis. However, for the reasons discussed above, the suspension that is subjected to ball milling preferably comprises from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof, more preferably from about 2% (w / w) to about 12% (w / w), even more preferably about 8% (w / w) to about 12% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof, and most preferably about10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis.
[0083] The suspension that is subjected to ball milling may comprise from about 75% (w / w) to about 99% (w / w) of the at least one semifluorinated alkane, preferably from about 85% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane, more preferably from about 88% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane, even more preferably from about 88% (w / w) to about 92% (w / w) of the at least one semifluorinated alkane, and most preferably about 90% (w / w) of the at least one semifluorinated alkane.
[0084] The suspension that is subjected to ball milling preferably consists essentially of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane. Therefore, the suspension that is subjected to ball milling may consist essentially of (a) from about 1% (w / w) to about 25% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 75% (w / w) to about 99% (w / w) of the at least one semifluorinated alkane. Preferably, the suspension that is subjected to ball milling consists essentially of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 85% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane. More preferably, the suspension that is subjected to ball milling consists essentially of (a) about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) about 90% (w / w) of the at least one semifluorinated alkane.
[0085] In a preferred example, the suspension that is subjected to ball milling consists of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane. Therefore, the suspension that is subjected to ball milling may consist of (a) from about 1% (w / w) to about 25% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 75% (w / w) to about 99% (w / w) of the at least one semifluorinated alkane. Preferably, the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 85% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane. More preferably, the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) about 90% (w / w) of the at least one semifluorinated alkane.
[0086] In a more preferred example, the suspension that is subjected to ball milling consists of lifitegrast or a pharmaceutically acceptable salt thereof and perfluorohexyloctane (F6H8). Therefore, the suspension that is subjected to ball milling may consist of (a) from about 1 % (w / w) to about 25% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 75% (w / w) to about 99% (w / w) of perfluorohexyloctane. Preferably, the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 85% (w / w) to about 98% (w / w) of perfluorohexyloctane. More preferably, the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) about 90% (w / w) of perfluorohexyloctane.
[0087] The ball milling step may comprise milling the particles of lifitegrast or a pharmaceutically acceptable salt thereof in a ball mill comprising balls having a diameter from about 0.05 mm to about 5 mm, preferably from about 0.1 mm to about 3 mm, more preferably from about 0.2 to about 1 mm, for example about 0.4 mm. Ball diameter is a standard form of sizing for balls used in ball mills. The ball mill may comprise balls made from alumina, zirconia, silicon nitride, or tungsten carbide, preferably zirconia.
[0088] Ball milling a suspension containing a higher concentration of lifitegrast improves the efficiency of the ball milling step and helps to achieve the desired particle diameter more quickly (providing the concentration of lifitegrast is not so high as to cause the suspension to be too viscous, as explained above). After milling, the suspension may be diluted to obtain the desired concentration of lifitegrast or a pharmaceutically acceptable salt thereof in the final suspension. Thus, the process preferably comprises adding a second portion of at least one semifluorinated alkane to the suspension after the suspension has been subjected to ball milling. The at least one semifluorinated alkane added after milling can be the same as or different to the at least one semifluorinated alkane present in the suspension that is ball milled. Preferably, the at least one semifluorinated alkane added after milling is the same as the at least one semifluorinated alkane present in the suspension that is ball milled.Container closure system
[0089] Further disclosed herein is a container closure system for dispensing an ophthalmic composition, such as system comprising a bottle or a vial, containing an ophthalmic composition as described above (i.e., in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at leastone semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less). The container closure system may contain any of the ophthalmic compositions described above and the particles of lifitegrast or a pharmaceutically acceptable salt thereof may have any of the D50 and D90 particle diameters mentioned above.
[0090] The container closure system may be a multi-dose container closure system. The container closure system may comprise or consist essentially of polypropylene.Methods for treatment of ocular disorders
[0091] Further disclosed herein are methods for the treatment and / or temporary prevention of at least one ocular disorder, comprising administering to a patient in need thereof an effective amount of an ophthalmic composition as described above.
[0092] Similarly provided is an ophthalmic composition as described above for use in a method for the treatment or temporary prevention of at least one ocular disorder.
[0093] Further provided is (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane for use in the manufacture of a medicament for the treatment or temporary prevention of at least one ocular disorder, preferably dry eye disease, wherein the medicament is an ophthalmic composition as described above.
[0094] The at least one ocular disorder may include, but is not limited to, dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, and the like.
[0095] The at least one ocular disorder may be chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, or any combination thereof.
[0096] The at least one ocular disorder may be chosen from conjunctivitis, keratitis, dry eye disease, or any combination thereof.
[0097] Preferably, the at least one ocular disorder is dry eye disease. The ophthalmic composition is particularly suitable for the treatment of dry eye disease and in particular for the treatment of mixed-type dry eye disease where the patient suffers from both aqueous deficient dry eye disease and evaporative dry eye disease, due to the presence of both lifitegrast and at least one semifluorinated alkane.
[0098] Therefore, the dry eye disease may be aqueous deficient dry eye disease. The dry eye disease may be evaporative dry eye disease. The suspension is particularly useful for treating patients wherein the dry eye disease is both aqueous deficient dry eye disease and evaporative dry eye disease.
[0099] The dry eye disease may have hyperosmolarity as a cause and / or as a symptom. The dry eye disease may have tear film instability as a cause and / or as a symptom. The dry eye disease may have both hyperosmolarity and tear film instability as a cause and / or as a symptom.
[0100] The method may comprise administering an effective amount of the ophthalmic composition in the form of one, two, three, or four droplets in each eye, preferably an effective amount of the ophthalmic composition in the form of one or two droplets in each eye, more preferably an effective amount of the ophthalmic composition in the form of one droplet in each eye.
[0101] The method may comprise administering the ophthalmic composition in each eye one, two, three, or four times daily. Preferably, the method may comprise administering the ophthalmic composition in each eye twice daily. This represents a reduced dosing frequency compared to an ophthalmic composition where perfluorohexyloctane is the sole active ingredient (Miebo™), which is typically administered four times daily.
[0102] Thus, the method may preferably comprise administering an effective amount of the ophthalmic composition in the form of one or two droplets in each eye one, two, three, or four times daily. More preferably, the method may comprise administering an effective amount of the ophthalmic composition in the form of one droplet in each eye twice daily.
[0103] The ophthalmic composition may be administered for at least 4 days, preferably for at least 10 days from the same multi-dose container closure system. Due to the preservative effect of the semifluorinated alkane and the resulting stability of the ophthalmic composition, the composition can be provided in a multi-dose container closure system without the addition of potentially irritating preservatives orantioxidants. This is more convenient to the user than a single dose unit and generates less packaging waste.
[0104] Preferably, the ophthalmic composition is administered from the same multidose container closure system twice daily in each eye for at least 4 days, more preferably for at least 10 days.
[0105] The examples support that ophthalmic compositions containing at least about 2% (w / w) lifitegrast will have good clinical efficacy against dry eye disease and will result in comparable or greater exposure of lifitegrast in the bulbar conjunctiva and cornea than a comparative aqueous solution. Thus, preferably, the method of treatment and / or temporary prevention of at least one ocular disorder, especially dry eye disease, comprises administering to a patient in need thereof an effective amount of an ophthalmic composition described above, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis. More preferably, the composition administered in the method consists of: (a) about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8). BRIEF DESCRIPTION OF DRAWINGS
[0106] Figure 1 shows cumulative lifitegrast concentrations (pg / g) in EpiCorneal™ tissue after 4 hours.
[0107] Figure 2 shows the concentration (ng / g) of lifitegrast measured in cornea over time (0-8 hours).EXAMPLESExample 1: Ball milling study
[0108] In the following examples, the particle size distribution was determined using a Horiba LA-960 particle analyser equipped with a Horiba MiniFlow circulation system, using the LA-960 for Windows V8.40 software and a Mie theory scattering model with a real and imaginary refractive index of 1.643 and 0.1 respectively. Before the measurement was taken, a dispersant of 0.1 % (w / w) sorbitan monooleate (Span® 80) in heptane was filtered through a 0.2 pm filter and added to the suspension of lifitegrast and F6H8 to give a mixture consisting of about 1% (w / w) suspension and about 99% (w / w) dispersant.
[0109] To investigate suitable ball milling conditions, slurries of lifitegrast free acid particles in perfluorohexyloctane (F6H8) were ball milled at different mill speeds in aFryma-Koruma CoBall Mill MS18 with 0.4 mm zirconium oxide (ZrC ) balls. The F6H8 used in these examples consisted essentially of 1 -perfluorohexyloctane and less than 0.5% (w / w) of 2-perfluorohexyloctane.Small scale studyBatch no. 1 2 3 4 Batch size (kg) 4 4 4 4 Concentration of lifitegrast (% w / w) 20 10 10 10 Number of passes through the mill 1 1 1 1Mill speed (m / s) 14 8 11 14 Pump speed (rpm) 6 30 15 6 Dio particle diameter (pm) 1.1 2.4 1.7 1.2 Dso particle diameter (pm) 1.8 4.4 3.6 2.5D90 particle diameter (pm) 3.3 7.4 6.9 6.0
[0110] At 20% (w / w) lifitegrast (batch 1), milling is feasible, but a paste forms that reduces the milling efficiency and makes the composition more difficult to handle. At 10% (w / w) lifitegrast, the composition has improved flowability. The particle size distribution improves with higher mill speed from batches 2 to 4. Smaller particle diameters are desirable to improve delivery of lifitegrast to the eye and to ensure that the delivery of lifitegrast is not limited by its dissolution rate.Clinical trial material (CTM) scale studyBatch no. 5 6 7 Batch size (kg) 25 25 25 Concentration of lifitegrast (% w / w) 10 10 10 Number of passes through the mill 1 2 1 Mill speed (m / s) 14 14 14 Pump speed (rpm) 6 6 30D10 particle diameter (pm) 1.0 1.0 2.3 Dso particle diameter (pm) 2.1 1.7 4.4D90 particle diameter (pm) 4.9 3.0 7.9
[0111] The smallest particle size distribution was obtained with batch 6, but the additional pass through the ball mill adds complexity to the manufacturing process. The faster pump speed for batch 7 resulted in a less favourable particle sizedistribution. The milling conditions for batch 5 result in desirable particle diameters and reduced manufacturing complexity and are therefore preferred.Example 2: Particle size and sedimentation study
[0112] This study investigated the sedimentation volume of different lifitegrast suspensions with different particle sizes and concentrations to assess the influence of milling time and dilution on stability.
[0113] Three bulk suspensions of lifitegrast free acid at a concentration of approximately 7.5% (w / w) in perfluorohexyloctane (F6H8) were prepared as Suspensions A to C.
[0114] Suspension A was ball milled for 48 hours in a Fryma-Koruma CoBall Mill MS18 with 0.4 mm zirconium oxide (ZrO2) balls. Suspension B was milled under the same conditions for 2 hours. Suspension C was not milled at all.
[0115] To evaluate the impact of concentration on sedimentation behaviour, each suspension was divided into five batches, which were diluted with F6H8 to obtain five different concentrations. The suspensions were then transferred into glass vials and stored undisturbed under ambient conditions for 48 hours, allowing for natural sedimentation. The sedimentation volume (F) was measured for each of the 15 suspensions to assess physical stability. The sedimentation volume was calculated as follows:Volume of settled sediment (l^) Sedimentation volume (F) = — - ; - ; - — - : - 7-—.Total volume of the suspension (Ft) Ideally, the sedimentation volume is 1 or close to 1. This represents a stable suspension where there is minimal or no sedimentation. A sedimentation volume of less than 0.09 represents an unacceptably unstable suspension.
[0116] To assess the impact of particle size distribution (PSD) on sedimentation behavior, the median particle diameter (Dso) of each suspension (A, B, and C) was measured using a Horiba LA-960 particle size analyzer. The table below summarises the concentration, Dso particle diameter, and sedimentation volume for all suspensions.Concentration of Sedimentation Suspension Dso particlediameter (pm) lifitegrast (% w / w) volume (F) A-1 0.923 7.25 1.000A-2 0.923 3.63 1.000A-3 0.923 1.81 0.938A-4 0.923 0.91 0.500A-5 0.923 0.45 0.406B-1 3.943 7.50 1.000B-2 3.943 3.75 1.000B-3 3.943 1.88 0.938B-4 3.943 0.94 0.688B-5 3.943 0.47 0.400C-1 6.329 7.50 1.000C-2 6.329 3.75 1.000C-3 6.329 1.88 0.500C-4 6.329 0.94 0.250C-5 6.329 0.47 0.133
[0117] All suspensions having a lifitegrast concentration of greater than about 3.6-3.75% (w / w) exhibited ideal suspension behaviour with a sedimentation volume of 1.
[0118] Suspension A (48-hour milling) had the smallest lifitegrast Dso particle diameter of 0.923 pm, and Suspension B (2-hour milling) had an intermediate lifitegrast Dso particle diameter of 3.943 pm. For lifitegrast concentrations of less than 2% (w / w), Suspensions A and B possessed similar sedimentation volumes at similar lifitegrast concentrations. However, both Suspensions A and B exhibited markedly higher sedimentation volumes and therefore greater stability than the corresponding concentrations for Suspension C. This shows that milling to reduce particle size, in particular to obtain a Dso particle diameter of about 4 pm or less, results in an improvement in suspension stability. However, the similar sedimentation behaviour of Suspensions A and B implies that continued milling to reduce the Dso particle diameter beyond about 4 pm is of limited further benefit.
[0119] Suspension C (unmilled) had the largest lifitegrast Dso particle diameter of 6.329 pm. For lifitegrast concentrations of less than 2% (w / w), Suspension C possessed lower sedimentation volumes and therefore lower stability than the corresponding concentrations for Suspensions A and B. Nevertheless, Suspension C still possessed good stability, especially at a concentration of about 2% (w / w) and above, and more especially at 3.75% (w / w) and above.
[0120] This study demonstrates that the concentration of suspended lifitegrast particles significantly affects sedimentation volume and therefore the stability of the suspension. It also shows that reducing particle size through milling improves suspension stability by increasing sedimentation volume. A suspension with higher stability is advantageous because it results in a more uniform dispersion of lifitegrast particles, which improves the consistency of the concentration of lifitegrast particles that is delivered to the eye with each drop of the ophthalmic composition.
[0121] It is shown in the examples of PCT / EP2024 / 082568 that stable, sterile suspensions of lifitegrast free acid and perfluorohexyloctane can be obtained without the addition of a preservative or antioxidant. It is further shown that these suspensions achieve similar ocular exposure as aqueous lifitegrast solutions at only one third of the dose.Example 3: F6H8 preservative activity
[0122] The antimicrobial properties of F6H8 were evaluated according to the Ph. Eur. 5.1.3 method. Results were as follows:Organism Time Count Log reduction Inoculum 2 x 105- 0 hour 16 4.1S. aureus 6 hours 0 5.324 hours 0 5.328 days 0 5.3Inoculum 8 x 105- 0 hour 5 x 1041.2P. aeruginosa 6 hours 4 x 1023.324 hours 8 5.028 days 0 5.9Inoculum 2 x 105- 0 hour 2 x 1041.0E. coli 6 hours 0 5.324 hours 0 5.328 days 0 5.3Inoculum 9 x 105- 0 hour 5 x 1032.3C. albicans7 days 0 6.028 days 0 6.0Inoculum 7 x 105- 0 hour 8 x 1040.9A. brasiliensis7 days 1 x 1032.828 days 2 x 1032.5
[0123] F6H8 meets the acceptance criteria for this assay, namely that (a) the concentrations of viable bacteria show not less than a 2 log reduction from the initial calculated count at 6 hours, not less than a 3 log reduction at 24 hours, and no recovery at 28 days and (b) the concentrations of yeasts and molds show not less thana 2 log reduction from the initial calculated count at 7 days, with no increase at 28 days. Thus F6H8 meets the antimicrobial effectiveness requirements without the need for extrinsic preservative.
[0124] This result can be explained by the lack of water activity in the F6H8 liquid. Addition of solid lifitegrast introduces no water activity and so this mixture also will not support microbial growth.Example 4: Suspensions
[0125] Lifitegrast free acid was added to F6H8 in various proportions, including (w / w) 0.25%, 1%, 2%, 2.5%, 4%, 5%, and 10%. The lifitegrast is in soluble in F6H8 and forms a suspension. When left standing the lifitegrast settles to form a sediment.
[0126] Lifitegrast is stable in the suspensions. During storage at 40°C levels of lifitegrast in a 4% suspension ( / .e. 96% (w / w) F6H8, 4% (w / w) lifitegrast) did not change:Time (months) 0 1 3Lifitegrast (%) 99.87 99.87 99.89
[0127] Similar results were seen in a 2% suspension. No significant impurities were seen when stored at 25°C for 3 months. A minor impurity increase was seen after 3 months at 40°C, but it was insignificant. Thus lifitegrast and F6H8 are chemically compatible. The same compatibility can be expected with other semifluorinated alkanes as they do not include any additional reactive groups.
[0128] Lifitegrast free acid / F6H8 suspensions were supplemented with a-tocopherol or tocopheryl acetate as antioxidants (e.g. 2% lifitegrast, 93% F6H8, 5% tocopheryl acetate). After storage for 1 month at 40°C levels of lifitegrast-derived impurities showed no significant differences with or without the antioxidants (e.g. for a 2% emulsion with 5% tocopheryl acetate the level of lifitegrast was 99.92% at time zero and still after 3 months at 40°C). Oxidation-derived degradation products were not detected with or without antioxidant. Lifitegrast and F6H8 are therefore compatible, without needing addition of any antioxidant.
[0129] Suspensions with 2% or 5% lifitegrast were subjected to centrifugation for 1 hour at 500, 750 or 1000 rpm to accelerate settling of the lifitegrast powder, and the ease and efficiency of redispersibility were evaluated by shaking the settled product by hand (conditions to mimic patient use). After 500 rpm centrifugation the powder could be resuspensed by one gentle inversion. After 750 or 1000 rpm centrifugationresuspension required several gentle inversions or shaking by hand 2 or 3 times. Thus the suspensions show redispersibility which is acceptable for patient use.
[0130] Suspensions were filled into polypropylene bottles with a dropper outlet and droplets were weighed. Droplets of F6H8 alone had a mass of 15.91 mg with a standard deviation of 0.55 mg, with a volume of 11.35 pL. Droplets of the 5% I ifitegrast suspension weighed 15.93 mg with a standard deviation of 0.43 mg, with a volume of 11.85 pL. Droplets of the suspensions thus show acceptable dose uniformity within a bottle, and lifitegrast does not interfere with the ability of F6H8 to form droplets.
[0131] Droplets of the F6H8 suspension are ~3x smaller than the aqueous droplets of Xiidra™ (5% lifitegrast solution), and so the amount of lifitegrast delivered by a single droplet of 5% suspension is lower than the amount delivered by a single Xiidra™ droplet.Example 5: Ocular irritation assessment
[0132] The ocular tolerability of lifitegrast free acid / F6H8 suspensions (5%) were assessed, including evaluation of sting / burn reactions relative to the marketed lifitegrast solution (Xiidra™) and the marketed F6H8 product (Miebo™). NZW rabbits (3 per group) received topical ocular doses QID for 5 Days (40 pL / dose = 160 pL / eye / day). Ocular irritation was assessed by (a) macroscopic examination (Draize scoring) after the fourth daily dose and, if irritation was noted, again in the following morning and (b) microscopic examination by slit lamp and indirect ophthalmoscopy at days 0 & 5. Sting / burn assessments were taken after the second and fourth daily dose, recording the cumulative duration of blinking / squinting and also noting other indicators (e.g., rubbing).
[0133] The suspensions were well tolerated with no toxicologically significant findings after 5 days of dosing.
[0134] The maximum weighted score for irritation in any animal was scored as 4 out of a maximum of 110. Suspensions were well tolerated and any negative effects (redness, discharge, conjunctival congestion) were short-lived and did not increase in seventy over the duration of the study.Example 6: Epicorneal tissue model
[0135] The EpiComeal 3D human tissue model (MatTek) provides a predictive non-animal model for assessing ophthalmic drug delivery. This model was used to assess the effect of F6H8 on lifitegrast permeability and the dose-dependence of permeability characteristics.
[0136] Seven formulations were tested: four suspensions (0.25%, 1%, 2.5% and 5%), a second 1% suspension, and two aqueous solutions (1% and 5%). 12 pL volumes were administered to the model and assessed for permeability (collecting 200 pL samples from the receiver at 15, 30, 60, 120, 180 and 240 minutes to measure penetrated lifitegrast concentration) and for lifitegrast concentration in EpiCorneal tissue after 240 minutes.
[0137] Suspensions had lower lifitegrast permeability than solutions but higher tissue accumulation. A dose-dependent increase in tissue accumulation was observed from 0.25% to 2.5% with the suspensions. Figure 1 shows cumulative lifitegrast concentrations in EpiCorneal tissue after 4 hours, indicating that the two 1% suspensions provided about the same performance as a 5% aqueous solution, and the 5% suspension provided higher tissue accumulation than the 5% solution. Slower permeation into the receiver using the suspensions might be explained by the need for the solid lifitegrast to dissolve before it can permeate.Example 7: Ocular pharmacokinetic study
[0138] An in vivo pharmacokinetic study was used to evaluate dose-dependent ocular bioavailability of lifitegrast free acid / F6H8 suspensions in dutch belted rabbits. Four suspensions were tested (10%, 5%, and 2x 1 %) and compared to a 5% aqueous solution:Cone. (%w / w)Ingredient5% sol" 1 % susp" 5% susp" 10% susp" Lifitegrast 5 1 5 10 Perfluorohexyloctane - 99 95 90 Sodium chloride 0.3 - - - Sodium thiosulfate 0.29 - - - Sodium phosphate - - - 0.35dibasicSodium hydroxide - - - 7.49(1 N) solutionPurified water q.s. - - -
[0139] The dosage volume per eye was 12 pL for the suspensions and 35 pL for the solution. Samples of cornea, bulbar conjunctiva, aqueous humor, anterior sclera, and palpebra conjunctiva were taken after 0.25, 1 , 3, and 8 hours. Corneal results are shown in Figure 2.
[0140] Dose-proportional ocular exposure of lifitegrast was seen with suspensions from 1-5%, with a higher than proportional increase in exposure at 10%.
[0141] Areas under the lifitegrast concentration-time curve from 0 to 8 hours (AUCo-8hr) were calculated with linear trapezoidal linear interpolation method using WinNonlin. Values were as follows, relative to the aqueous solution (100%):5% sol" 1 % SUSP" 1 % SUSP" 5% susp" 10% susp" Cornea 100 11 9 77 148 B.conj 100 36 28 212 642 P.conj 100 27 17 150 552Aq humor 100 14 13 55 309Sclera 100 13 15 60 195
[0142] The 5% suspension dose at 12 pL gave the most similar ocular exposure to 5% solution dosed at 35 pL. Thus the administered amount of lifitegrast can be reduced 3-fold while achieving the same ocular exposure.
[0143] Maximum observed concentration (Cmax) values were determined relative to the aqueous solution (100%):5% sol" 1 % susp" 1 % susp" 5% susp" 10% susp" Cornea 100 10 10 72 115 B.conj 100 36 68 216 706 P.conj 100 27 30 179 525Aq humor 100 14 18 115 688Sclera 100 21 35 132 177
[0144] The 5% suspension in F6H8 achieved an approximately two-fold increase in Cmax and AUCo-shr in the conjunctiva, despite the total dose of lifitegrast being about one third of the dose administered with the 5% aqueous solution (due to the difference in droplet size). Without being bound by theory, the conjunctiva is an important tissue in the pathology of dry eye disease because it is the site of mucin-secreting goblet cells, which are important for tear film quality and can be damaged by inflammation. Moreover, the conjunctiva is believed to be the primary site of immune cells on the ocular surface, which makes it a likely primary site of action for lifitegrast. Therefore, the increase in Cmax and AUCo-shr in the conjunctiva means that the total dose of lifitegrast can be lowered (e.g., by using a smaller drop of a similar dose-strength) while delivering more of the drug to the presumed primary site of action.Example 8: Human pharmacokinetic modelling data
[0145] A nonparametric superpositioning (NSP) method implemented in Pheonix WinNonlin software was used to model single dose pharmacokinetic data from rabbits and to simulate steady state drug exposure at the human conjunctiva and cornea based on those data.
[0146] The model used the following lifitegrast concentration data in the bulbar conjunctiva and cornea of rabbits following administration of a single drop of 12 pL of a suspension of 5% (w / w) and 1% (w / w) lifitegrast in F6H8 or 35 pL of an aqueous solution of 5% (w / w) lifitegrast. The difference in drop size means that the delivered dose of lifitegrast from a single drop of the aqueous solution is more than double the dose of lifitegrast from a single drop of the suspension for the same concentration of lifitegrast. The data relating to 1% and 5% lifitegrast / F6H8 suspensions were used to simulate steady state drug exposure of 1%, 1.5%, 2%, 2.5% and 5% suspensions in humans dosed with a 12 pL drop BID for 3 days. The data relating to 5% lifitegrast aqueous solution were used to simulate steady state drug exposure of 0.1%, 1% and 5% aqueous solutions in humans dosed with a 35 pL drop BID for 3 days. The conversion involved multiplying the exposure in rabbits by 40% to convert the exposure values to expected exposure in humans.Lifitegrast concentrations in B. conjunctiva and cornea in rabbits following a single drop of 12 L of a suspension ora single drop of 35 pL of a solution Concentration (ng / g)Tissue Formulation0.25 1 h 3 h 8 h5% Solution 18300 7200* 19400 6690 B. Conj 1% Suspension 6100 2240* 6910 28205 % Suspension 41900 41900 24700 21800 5% Solution 7020 5130 4930 2240 Cornea 1 % Suspension 666.7 471.3 641.6 197.35 % Suspension 5040 3060 4280 1570‘Handled as outliers. The outliers were removed and imputed with extrapolated values based on first order elimination.
[0147] The model makes the following assumptions:• Each dose acts independently• There is no change in absorption between doses• There is no change in clearance between doses• Linear kinetics apply (dose proportionality)
[0148] The following results predict exposure in human bulbar conjunctiva at steady state:Formulation Cmax (ng / g) Ctau (ng / g) AUCtau (ng -h / g) 5% Suspension 10416 3840 755005% Solution 9321 1910 636832.5% Suspension 5208 1920 377502% Suspension 4179 1536 302081.5% Suspension 3134 1152 226561% Suspension 3547 969 260261% Solution 1864 382 12737Note: Cmax, Ctau and AUCtau of LIF in human B. conjunctiva were obtained in the simulated profile between 60 to 72 hours.
[0149] The following results predict exposure in human cornea at steady state: Formulation Cmax (ng / g) Ctau (ng / g) AUCtau (ng-h / g) 5% Suspension 2498 579 157225% Solution 3394 720 203652.5% Suspension 1249 290 78612% Suspension 1030 232 64891.5% Suspension 485 88 29931% Suspension 313 59 19951% Solution 679 144 4073Note: Cmax, Ctau and AUCtau of LIF in human cornea were obtained in the simulated profile between 60 to 72 hours.
[0150] Both 1% and 5% aqueous solutions of lifitegrast are known to have clinical efficacy, as reported in Semba et al. Am J Ophthalmol, 2012;153:1050-1060. Therefore, results relating to the suspension that show a comparable or higher exposure to lifitegrast than the results relating to the 1% and 5% aqueous solutions are also expected to be clinically efficacious.
[0151] In the bulbar conjunctiva, which is believed to be a primary site of action of lifitegrast, the simulated results for the 5% suspension surprisingly predict greater exposure than for the 5% aqueous solution, and likewise, the simulated results for the 1-2.5% suspensions predict greater exposure than the 1% aqueous solution. This is even more surprising given the smaller drop size, and therefore smaller dose of lifitegrast, for the suspensions compared to the aqueous solutions. For the same reasons, it was also surprising that the simulated results for 2-2.5% suspensionspredict greater exposure in the cornea, which is also an important site of action for lifitegrast, than for the 1% aqueous solution. This data therefore indicates that suspensions of lifitegrast in F6H8, and in particular suspensions containing at least about 2% (w / w) lifitegrast (e.g., suspensions comprising about 2% (w / w) to about 6% (w / w) lifitegrast), will have good clinical efficacy and result in comparable or greater exposure of lifitegrast in the bulbar conjunctiva and cornea than a higher dose of the aqueous solution at the same concentration.
[0152] It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.NUMBERED EMBODIMENTSAn ophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less.The ophthalmic composition of numbered embodiment 1 , wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter of about 10 pm or less, for example from about 3 pm to about 10 pm.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter of about 7 pm or less, for example from about 3 pm to about 7 pm.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter of about 7 pm or less, for example from about 0.5 pm to about 7 pm.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter of about 4 pm or less, for example from about 0.5 pm to about 4 pm.The ophthalmic composition of numbered embodiment 1 , wherein the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less.The ophthalmic composition of numbered embodiment 1 , wherein the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of from about 3 pm to about 10 pm and (ii) a D50 particle diameter of from about 0.5 pm to about 7 pm.The ophthalmic composition of numbered embodiment 1 , wherein the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of from about 3 pm to about 7 pm and (ii) a D50 particle diameter of from about 0.5 pm to about 4 pm.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the particle diameter is determined by laser diffraction.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition consists of: (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane.The ophthalmic composition of any one of numbered embodiments 1 -10, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) no more than two semifluorinated alkanes.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition consists of: (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) no more than two semifluorinated alkanes.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane is chosen from F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof; optionally wherein the composition includes no more than two semifluorinated alkanes.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane comprises at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition comprises perfluorohexyloctane (F6H8) and is substantially free of other semifluorinated alkanes.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition consists of: (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane (F6H8).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 0.1% (w / w) to about 10% (w / w) ona free acid basis, for example from about 2% (w / w) to about 8% (w / w) on a free acid basis.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w) on a free acid basis.The container closure system of any one of the preceding numbered embodiments, wherein the composition consists of: (a) about 2% (w / w) to about 8% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, for example about 2% (w / w) to about 6% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) perfluorohexyloctane (F6H8).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2.5% (w / w) to about 5% (w / w) on a free acid basis.The container closure system of any one of the preceding numbered embodiments, wherein the composition consists of: (a) about 2.5% (w / w) to about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration of about 2.5% (w / w) on a free acid basis. The ophthalmic composition of any one of numbered embodiments 1-23, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration of about 5% (w / w) on a free acid basis.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition consists essentially of: (a) about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition consists of: (a) about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8).The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter of about 4 pm or less, for example from about 0.5 pm to about 4 pm, and is included in the composition at a concentration of about 2% (w / w) or more, for example from about 2% (w / w) to about 8% (w / w), on a free acid basis The ophthalmic composition of any one of the preceding numbered embodiments, wherein the lifitegrast is in the form of lifitegrast free acid.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition is at least one of (i) substantially free of medium chain triglycerides and (ii) substantially free of semifluorinated alkyl alcohols, preferably wherein the composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.The ophthalmic composition of any one of the preceding numbered embodiments, wherein the composition is at least one of (i) substantially free of an antioxidant and (ii) substantially free of a preservative, preferably wherein the composition is substantially free of an antioxidant and substantially free of a preservative.A container closure system for dispensing an ophthalmic composition comprising the composition as defined in any one of numbered embodiments 1-31.A method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of numbered embodiments 1-31. The method according to numbered embodiment 33, wherein the at least one ocular disorder is chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, or any combination thereof.The method according to numbered embodiment 33 or numbered embodiment 34, wherein the at least one ocular disorder is chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis,allergic conjunctivitis, endophthalmitis, keratitis, uveitis, or any combination thereof.The method according to any one of numbered embodiments 33-35, wherein the at least one ocular disorder is chosen from conjunctivitis, keratitis, dry eye disease, or any combination thereof.The method according to any one of numbered embodiments 33-36, wherein the at least one ocular disorder is dry eye disease, preferably wherein the at least one ocular disorder is evaporative dry eye disease and aqueous deficient dry eye disease.The method according to any one of numbered embodiments 33-37, wherein the method comprises administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of numbered embodiments 1-31, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis. A process for reducing the particle diameter of solid lifitegrast or a pharmaceutically acceptable salt thereof, the process comprising ball milling a suspension of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane.A process for preparing the ophthalmic composition of any one of numbered embodiments 1-31, the process comprising ball milling a suspension of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof.The process of numbered embodiment 39 or numbered embodiment 40, wherein the process comprises adding a second portion of the at least one semifluorinated alkane to the suspension after the suspension has been subjected to ball milling. The process of any one of numbered embodiments 39-41 , wherein the suspension that is subjected to ball milling comprises from about 1 % (w / w) to about 25% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of numbered embodiments 39-42, wherein the suspension that is subjected to ball milling comprises from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof, for example about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of numbered embodiments 39-43, wherein the suspension that is subjected to ball milling comprises from about 75% (w / w) to about 99% (w / w) of the at least one semifluorinated alkane.The process of any one of numbered embodiments 39-44, wherein the suspension that is subjected to ball milling comprises from about 85% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane, for example about 90% (w / w) of the at least one semifluorinated alkane.The process of any one of numbered embodiments 39-45, wherein the suspension that is subjected to ball milling consists essentially of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane, for example wherein the suspension that is subjected to ball milling consists essentially of (a) about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of the at least one semifluorinated alkane.The process of any one of numbered embodiments 39-46, wherein the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of the at least one semifluorinated alkane, for example wherein the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of the at least one semifluorinated alkane. The process of any one of numbered embodiments 39-47, wherein the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of perfluorohexyloctane, for example wherein the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of perfluorohexyloctane.The process of any one of numbered embodiments 39-48, wherein the process comprises micronising the lifitegrast or a pharmaceutically acceptable salt thereof before ball milling.The process of any one of numbered embodiments 39-49, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 10 pm or less, for example from about 3 pm to about 10 pm, and a D90 particle diameter before ball milling of at least about 11 pm, for example from about 11 pm to about 25 pm.The process of any one of numbered embodiments 39-49, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 7 pm or less, for example from about 3 pm to about 7 pm, and a D90 particle diameter before ball milling of at least about 8 pm, for example from about 8 pm to about 12 pm.The process of any one of numbered embodiments 39-51, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 7 pm or less, for example from about 0.5 pm to about 7 pm, and a D50 particle diameter before ball milling of at least about 8 pm, for example from about 8 pm to about 12 pm.The process of any one of numbered embodiments 39-51, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 4 pm or less, for example from about 0.5 pm to about 4 pm, and a D50 particle diameter before ball milling of at least about 5 pm, for example from about 5 pm to about 10 pm.The process of any one of numbered embodiments 39-53, wherein the ball milling reduces the D90 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least 10%, for example from about 10% to about 95%.The process of any one of numbered embodiments 39-54, wherein the ball milling reduces the D50 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least 10%, for example from about 10% to about 95%.The process of any one of numbered embodiments 39-55, wherein the ball milling step comprises milling the particles of lifitegrast or a pharmaceutically acceptable salt thereof in a ball mill comprising balls having a diameter from about 0.05 mm to about 5 mm, for example from about 0.1 mm to about 3 mm, for example from about 0.2 to about 1 mm.The process of any one of numbered embodiments 39-56, wherein the ball mill comprises balls made from alumina, zirconia, silicon nitride, or tungsten carbide, for example wherein the balls are made from zirconia.
Claims
CLAIMS1. An ophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has at least one of (i) a D90 particle diameter of about 10 pm or less and (ii) a D50 particle diameter of about 7 pm or less.
2. The ophthalmic composition of claim 1, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter of about 10 pm or less, for example from about 3 pm to about 10 pm.
3. The ophthalmic composition of claim 1, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter of about 7 pm or less, for example from about 3 pm to about 7 pm.
4. The ophthalmic composition of claim 1 or claim 2, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter of about 7 pm or less, for example from about 0.5 pm to about 7 pm.
5. The ophthalmic composition of any one of the preceding claims, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter of about 4 pm or less, for example from about 0.5 pm to about 4 pm.
6. The ophthalmic composition of claim 1, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of from about 3 pm to about 10 pm and (ii) a D50 particle diameter of from about 0.5 pm to about 7 pm.
7. The ophthalmic composition of claim 1, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has (i) a D90 particle diameter of from about 3 pm to about 7 pm and (ii) a D50 particle diameter of from about 0.5 pm to about 4 pm.
8. The ophthalmic composition of any one of the preceding claims, wherein the composition comprises perfluorohexyloctane (F6H8) and is substantially free of other semifluorinated alkanes.
9. The ophthalmic composition of any one of the preceding claims, wherein the composition consists of: (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane (F6H8).
10. The ophthalmic composition of any one of the preceding claims, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in thecomposition at a concentration from about 0.1% (w / w) to about 10% (w / w) on a free acid basis.
11. The ophthalmic composition of any one of the preceding claims, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 8% (w / w) on a free acid basis.
12. The ophthalmic composition of any one of the preceding claims, wherein the composition consists of: (a) about 2% (w / w) to about 8% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, for example about 2% (w / w) to about 6% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) perfluorohexyloctane (F6H8).
13. The container closure system of any one of the preceding claims, wherein the composition consists of: (a) about 2.5% (w / w) to about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8).
14. The ophthalmic composition of any one of the preceding claims, wherein the composition consists of: (a) about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8).
15. The ophthalmic composition of any one of the preceding claims, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter of about 4 pm or less, for example from about 0.5 pm to about 4 pm, and is included in the composition at a concentration of about 2% (w / w) or more, for example from about 2% (w / w) to about 8% (w / w), on a free acid basis.
16. The ophthalmic composition of any one of the preceding claims, wherein the lifitegrast is in the form of lifitegrast free acid.
17. The ophthalmic composition of any one of the preceding claims, wherein the composition is at least one of (i) substantially free of medium chain triglycerides and (ii) substantially free of semifluorinated alkyl alcohols, preferably wherein the composition is substantially free of medium chain triglycerides and substantially free of semifluorinated alkyl alcohols.
18. The ophthalmic composition of any one of the preceding claims, wherein the composition is at least one of (i) substantially free of an antioxidant and (ii) substantially free of a preservative, preferably wherein the composition is substantially free of an antioxidant and substantially free of a preservative.
19. A container closure system for dispensing an ophthalmic composition comprising the composition as defined in any one of claims 1-18.
20. A method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of claims 1-18.
21. The method according to claim 20, wherein the at least one ocular disorder is chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, or any combination thereof.
22. The method according to claim 20 or claim 21, wherein the at least one ocular disorder is dry eye disease.
23. The method according to any one of claims 20-22, wherein the method comprises administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of claims 1-18, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis.
24. A process for reducing the particle diameter of solid lifitegrast or a pharmaceutically acceptable salt thereof, the process comprising ball milling a suspension of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane.
25. A process for preparing the ophthalmic composition of any one of claims 1 -18, the process comprising ball milling a suspension of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof.
26. The process of claim 24 or claim 25, wherein the process comprises adding a second portion of the at least one semifluorinated alkane to the suspension after the suspension has been subjected to ball milling.
27. The process of any one of claims 24-26, wherein the suspension that is subjected to ball milling comprises from about 2% (w / w) to about 15% (w / w) of the lifitegrastor a pharmaceutically acceptable salt thereof, for example about 10% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof.
28. The process of any one of claims 24-27, wherein the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of perfluorohexyloctane.
